Navigation Links
Schering-Plough Reports Top-Line Results of the IDEAL Study
Date:1/14/2008

tners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the IDEAL study and the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's third quarter 2007 10-Q.

References:

1 Pegasys and Copegus are registered trademarks of Hoffmann-La Roche Inc.


'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
2. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Second Thoughts about Fluoride, Reports Scientific American
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
9. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 2014 NeuroCall, Inc., ("NeuroCall") announced today that ... and Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder ... extremely proud that our quality of service has been ... provide lifesaving support and continuity of care to patients ... the United States ." ...
(Date:10/1/2014)... LOUIS , Oct. 1, 2014  Express Scripts ... two nationally available 2015 Express Scripts Medicare ® ... pharmacy network featuring Walgreens (NYSE: WAG ) ... more value, choice and clinical support  for their Medicare ... Express Scripts Medicare Value or Choice ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... -- LEUVEN, Belgium, September 6, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... O R R E C T I O N - Mindray Medical... -- SHENZHEN, China, Aug. 25 /PRNewswire-Asia-FirstCall/ ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10/C O R R E C T I O N - Mindray Medical International Limited / 2/C O R R E C T I O N - Mindray Medical International Limited / 3/C O R R E C T I O N - Mindray Medical International Limited / 4/C O R R E C T I O N - Mindray Medical International Limited / 5/C O R R E C T I O N - Mindray Medical International Limited / 6/C O R R E C T I O N - Mindray Medical International Limited / 7
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... 2014 Familylifeinsurancequotes.org has released a ... for senior citizens. , Senior citizens can qualify ... sell coverage to seniors who are over 50 years ... without taking a medical examination. , Term life insurance ... senior clients can qualify. Having life insurance during retirement ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2
... an Army leader and a military surgeon are among the ... the Henry M. Jackson Foundation for the Advancement of Military ... which will take place at the National Museum of Women ... by service members, veterans and civilians who are working together ...
... News) -- Prenatal diagnosis, early surgery and well-coordinated care by ... cleft lip and/or cleft palate, experts say. Cleft lip ... pregnancy when the roof of the mouth fails to fuse ... United States each year and is the second most common ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... A gene known to be important in cardiac development ... result in obstruction of the left ventricular outflow tract. ... Nationwide Children,s Hospital and appearing in the journal ... outflow tract (LVOT) malformations, including aortic valve stenosis, coarctation ...
... Australia and Europe. Large resources are set aside for research ... the research field is still new but researchers from ... years ago the Norwegian health care system had a low ... sectors", says Professor Karina Aase at the University of Stavanger. ...
... in powerful positions are just as likely as men to cheat ... that men are more likely than women to cheat on their ... gender, according to the study published April 28 in the journal ... research in the past that indicates that gender is the strongest ...
Cached Medicine News:Health News:Dinner to honor icons of military medicine 2Health News:Early Surgery Boosts Outcomes for Babies With Cleft Palate 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:Study identifies second gene associated with specific congenital heart defects 2Health News:Sustaining vulnerable lives 2Health News:Sustaining vulnerable lives 3Health News:Powerful Women as Likely to Cheat as Men, Study Finds 2
Double ended 1.75 mm by 30 mm sterling silver blade. Flat serrated handle with polished finish....
4 mm wide by 17.5 mm flat platinum spatula on 34 mm shaft. Flat serrated handle with polished finish. Most popular size or model....
... Duckbilled spatula designed to enter ... broad enough to efficiently manipulate the ... Spatula is useful for rotating and ... rounded tip with notch and curved ...
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Medicine Products: